BURLINGTON, Mass., September 3, 2002 - Emptoris, Inc., a leading provider of collaborative strategic sourcing solutions, today announced that GlaxoSmithKline (NYSE:GSK) has selected Emptoris’ ePASS as the sourcing platform for its global strategic sourcing initiatives. Under the terms of the agreement, GlaxoSmithKline will implement ePASS, a portfolio of collaborative sourcing solutions, across the enterprise, including the United States, United Kingdom, and other major European and international countries.
By implementing ePASS, GlaxoSmithKline will be able to perform all of its global strategic sourcing processes -- including supplier qualification, RFx management, reverse auctions, and multi-stage, Internet-based negotiations -- online. Through optimization-based decision support technology, Sourcing Group Managers across all of GlaxoSmithKline’s business sectors can quickly analyze all purchasing scenarios using scientific algorithms to determine the optimal supply-base allocation. The combination of advanced auction, robust quoting, comprehensive data management and sophisticated decision support capabilities will enable GlaxoSmithKline to lower purchased goods and service costs, improve supplier performance and achieve faster cycle times.
“Each business unit of GlaxoSmithKline has unique, complex decision factors that need to be taken into account when making sourcing decisions,” said R. Gregg Brandyberry, Director Global Systems and Processes, GlaxoSmithKline Procurement. “We evaluated twelve sourcing solutions and chose ePASS because it was clearly the market leader in terms of the functionality required to take us to the next level in sourcing.”
“We’re on a mission to be the best procurement organization regardless of industry,” commented Willie A. Deese, Sr. Vice President, GlaxoSmithKline Procurement. “The breadth and depth of the Emptoris solution will allow us to bring more spend categories online quicker, thus driving a faster return on investment. In addition, ePASS was the only solution we evaluated that had true optimization-based decision support which will enable us to very quickly execute sophisticated bid analysis guaranteeing that we have the lowest total cost result.”
“The pharmaceutical industry is yet another market that can greatly benefit from advanced e-sourcing solutions to enable the sourcing of complex goods and services online,” said Avner Schneur, President and CEO of Emptoris. “GlaxoSmithKline has gained a reputation as a company that uses leading-edge technology to automate and optimize a number of its business processes. By implementing ePASS, GlaxoSmithKline will be able to substantially improve its bottom line by guaranteeing that it is maximizing cost savings in the area of supply-base allocation. GlaxoSmithKline’s selection of Emptoris is more evidence that ePASS is the leading e-sourcing solution on the market today.”
About GlaxoSmithKline
GlaxoSmithKline, one of the world's leading research-based pharmaceutical and healthcare companies, is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
About Emptoris
Emptoris is a leading provider of collaborative sourcing solutions that support the end-to-end strategic sourcing needs of Global 5000 companies. By implementing Emptoris’ ePASS, a portfolio of Web-based collaborative sourcing solutions, enterprises can streamline the strategic sourcing process, determine the optimal allocation of business among suppliers and forge tighter supplier relationships. Key benefits include lower costs, shorter sourcing cycles and improved buyer/supplier collaboration. Emptoris, a privately held company, is headquartered in Burlington, Massachusetts.
In the News 
